Celldex Therapeutics CLDX Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's other accrued liabilities?
- Celldex Therapeutics (CLDX) reported other accrued liabilities of $1.23M in Q1 2026.
- How has Celldex Therapeutics's other accrued liabilities changed year-over-year?
- Celldex Therapeutics's other accrued liabilities decreased by 25.6% year-over-year, from $1.65M to $1.23M.
- What is the long-term trend for Celldex Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Celldex Therapeutics's other accrued liabilities has grown at a -18.3% compound annual growth rate (CAGR), from $3.37M to $1.23M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.